- Trial phase
- Approved (FDA approval 2021-09-28 per SecBot catalyst record); post-approval Phase 3 programs completed
- Time to market
- Already on the US market since September 2021 as Qulipta (atogepant); "Aquipta" is the same molecule's international/EU brand name.
- Why 3/10
- No hard, dated binary in the next ~12 months: atogepant was already FDA-approved (QULIPTA approval catalyst recorded 2021-09-28), its three tracked Phase 3 trials are COMPLETED with results, and no pending PDUFA/readout for this molecule appears in SecBot's FDA-catalyst data, so it lands at 3 (approved & commercializing, no pending decision, small slice of a mega-cap).
ABBV's analyst tape is bullish (mean target ~$270 vs ~$251 price), but that thesis rests on the whole portfolio, not this drug.
Price Chart
Executive Summary
Aquipta is the international brand name for atogepant, the once-daily oral migraine-prevention pill AbbVie sells in the US as Qulipta. The drug is approved and commercializing; its remaining tracked activity is three completed Phase 3 studies (vs topiramate, with Botox in chronic migraine, and in Japanese patients) that could support label expansion or global positioning.
How It Works
Atogepant is a small-molecule pill ("gepant" class) that blocks the CGRP pathway, a protein signaling system involved in triggering migraine attacks. Taken once daily, it is designed to prevent migraines from happening rather than treating them after onset, an oral alternative to injectable antibody preventives.
Trial Status
Three AbbVie-sponsored Phase 3 trials of atogepant are marked COMPLETED in SecBot's ClinicalTrials.gov-derived data: NCT05748483 (atogepant vs topiramate, 545 enrolled, primary completion 2025-04-28, results posted), NCT05216263 (atogepant added to onabotulinumtoxinA/Botox in chronic migraine, 75 enrolled, completed 2025-05-02, results posted), and NCT05861427 (atogepant in Japanese episodic-migraine patients, 524 enrolled, completed 2025-03-01, results posted).
The Two-Sided Case
Upcoming Catalysts
- None scheduled for atogepant specifically; watch AbbVie quarterly earnings (latest 8-K filed 2026-07-31) for migraine-franchise sales trends
- Potential label-expansion or international-launch announcements tied to the completed Phase 3 data (topiramate head-to-head, chronic-migraine add-on with Botox, Japan episodic-migraine trial)
- Any EU/EMA or regulatory updates on the Aquipta brand (could not be verified this session due to the web-search outage)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report